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Summary Cancer chemoprevention is fast becoming a lucrative approach for controlling
cancer. Carcinogenesis being a complex multi-step, multi-factorial process, a number of
chemopreventive interventions can be employed. These strategies are generally directed
against two broad events of carcinogenesis viz., initiation and promotion/progression. Anti-
initiation interventions principally involve inhibition of carcinogen activation, scavenging of
free radicals and reactive carcinogen metabolites along with enhanced detoxification of
carcinogens by modulating cellular metabolism. Anti-promotion strategies involve attenuation
of enhanced cellular proliferation along with induction of cellular apoptosis and differentiation.
Dietary agents or herbal anti-oxidants due to low toxicity and relative safety are promising
chemopreventive agents. These agents after emerging successful through a series of in vitro
and in vivo assays enter clinical trials. Many dietary compounds have emerged as promising
chemopreventive agents in empirical experiments. However, in clinical trials these compounds
have met with limited success. This emphasizes the need for further detailed research on the
mechanisms of observed chemoprevention and choice, dose, duration and bioavailability of
chemopreventive agent used. Complex issues such as choice and nutritional status of target
population, genetic variation, gene-environment interactions and relevance of biomarkers
analyzed also warrant further research and analyses.
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Introduction
Majority of human cancers are caused, mediated or modified
by exogenous/endogenous environmental factors. Epidemio-
logical studies have successfully demonstrated that certain
well-defined exposures (e.g. tobacco, alcohol, ionizing radi-
ation, occupational carcinogens and viruses etc.) increase
the risk of cancers at specific sites, which have also been
supported by in vivo experimental studies. A few associations
like tobacco use and oral cancer have been established to be
causative while for many other associations, their role in
causation of cancer still remains to be established. Further, the
identification of specific causative factors and evaluation of
their relative importance has proved to be rather difficult since
majority of cancers result from complex interactions between
environmental and host factors [1]. Efforts to eliminate
known human carcinogens like tobacco from the environment
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and current treatment approaches have met with limited
success. Based on the experience with some infectious
diseases and the recent progress in cardiology, prevention of
diseases appears to be one of the achievable, cost effective
and attractive approaches. Thus, cancer prevention serves as
a promising approach to decrease cancer burden.
Cancer chemoprevention can be defined as the use of
natural or synthetic compounds to prevent, suppress or delay
the development of invasive carcinoma. Chemoprevention
offers a promising approach to primary cancer prevention for
a variety of organ systems. Based on empirical experiments
and clinical evaluations many compounds belonging to
diverse chemical classes have been identified as potential
chemopreventive agents [2]. These include vitamins, minerals,
naturally occurring phytochemicals and synthetic compounds.
The scientific rationale for the use of cancer chemo-
prevention is based on the fundamental concept of multi-step
carcinogenesis. Carcinogenesis is a long evolving process
which can be broadly divided into two principal steps viz.,
initiation where normal cells acquire mutations via environ-
mental mutagens, viruses etc. followed by promotion/
progression where the initiated/mutant cells clonally expand
and further transform to give rise to neoplasia. Thus inhibition
of any stage of carcinogenesis by any agent can potentially
prevent cancer [3] (Fig. 1).
Cellular Metabolism and Carcinogenesis
Cellular metabolism plays a very critical role in the process
of initiation during carcinogenesis [4]. Xenobiotics entering
the cellular environment are metabolized by phase I and phase
II enzymes. Phase I enzymes, predominantly Cytochrome
P450s (CYP450s—a super family of heme-thiolate enzymes),
are involved in the first step of metabolism where xeno-
biotics are processed to more electrophilic moieties for further
detoxification by phase II enzymes [5]. This step can be
termed as bioactivation which renders pro-carcinogens to
reactive intermediates and these in turn can form bio-
molecular adducts e.g. DNA-adducts, protein-adducts etc.
which mark the process of initiation. Thus, decreased activation
of carcinogens due to modulation of the CYP 450 enzymes
could be one of the plausible targets for chemoprevention to
prevent the cancer initiation process. CYP1-CYP9 family
of enzymes which are principally involved in xenobiotic
metabolism have distinct substrate specificities and are
differentially regulated by different ligands which interact
with endogenous receptors like aryl hydrocarbon receptor
(AhR) and pregnane X receptor (PXR). AhR is one of the
well studied receptors involved in induction of CYP1A sub-
family enzymes which are primarily involved in metabolizing
xenobiotics like poly aromatic hydrocarbons (PAHs). AhR is
a ligand dependent transcription factor and member of the
basic-helix-loop-helix family. In an unliganded or inactive
state the receptor is present in the cytoplasm in a complex
with two molecules of molecular chaperones, hsp90, an
immunophilin like protein, XAP-2 and the hsp90 interacting
protein, p23. Upon ligand binding, the ligand-AhR-hsp90-
XAP2-p23 complex translocates to nucleus where hsp90-
XAP2-p23 dissociates from the ligand-AhR complex. This
ligand-AhR complex further associates with a structurally
related protein, AhR nuclear translocator (ARNT). This
ligand bound AhR-ARNT complex recognizes consensus
sequences termed xenobiotic response elements (XREs) to
modulate the expression of downstream genes. Certain
chemopreventive agents, like plant flavanoids, have shown
to act as natural ligands of AhR and hence not only compete
for binding with PAHs but also block subsequent nuclear
translocation and DNA binding followed by transactivation
of CYP genes [6]. Such agents, that can block pro-carcinogen
activation, can serve as potential blockers of initiation of
carcinogenesis (Fig. 2).
In the next step of metabolism, detoxification by phase II
enzymes decrease the burden of bio-molecular adducts by
eliminating the reactive-intermediates from cellular environ-
ment. Activated pro-carcinogens are conjugated with endog-
enous bio-molecules like glutathione (GSH) or glucuronic
acid by phase II enzymes rendering them less toxic and more
water soluble, thus blocking the process of initiation [5].
Hence, any agent that can alter this cellular metabolism by
inducing phase II enzymes to block the process of initiation
of carcinogenesis can be employed as a potential chemo-
preventive agent. Unlike phase I enzymes, phase II enzymes
or more frequently referred as cyto-protective enzymes are
regulated by common upstream promoter regulatory element
called ARE (anti-oxidant response element) [7]. Thus, many
enzymes regulated by this promoter element are referred as
phase II enzymes and their inducibility can be exploited as
potential chemopreventive strategy. Some of the most
commonly exploited detoxifying enzymes are glutathione S-
transferases (GSTs), UDP-glucuronosyltransferases, NADPH
Fig. 1.  Chemopreventive agents can prevent cancer by inhibit-
ing the process of carcinogenesis either by inhibiting ini-
tiation and/or promotion event.R. Patel, et al.
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quinone oxidoreductase I (NQO1) and certain other anti-
oxidant enzymes like superoxide dismutase, catalase etc.
Agents that induce phase II enzymes bring about activation
of ARE by activating an obligate transcription factor
Nuclear Erythroid Factor 2 – Related Factor 2 (Nrf2), member
of the Cap ‘n’ Collar family of basic region leucine b-ZIP
transcription factor. Nrf2 heterodimerizes with array of
leucine b-zip family members like small maf proteins, jun,
fos etc. to either upregulate or inhibit transcription through
ARE. Nrf2 under normal uninduced cellular environment
is strictly regulated by its cytosolic inhibitor Keap1 which
in turn is bound to actin cytoskeleton. Upon activation Nrf2
is released from Keap1 and translocates to nucleus where
it binds to ARE after heterodimerizing to other leucine
zipper proteins to transciptionally activate the downstream
genes. Activating signals are generally regulated by ROS
modulation in cells where a number of signaling molecules
might interplay in cell type specific manner [7]. Most
chemopreventive agents are modulators of cellular ROS and
hence activate Nrf2 pathway, which in turn induces phase II
detoxifying enzymes thus blocking initiation event (Fig. 3).
In addition to bioactivation of xenobiotics, oxidative
damage to DNA, proteins and lipids in human body due to
exposure to endogenous or exogenous chemical agents,
chronic infections and inflammations, is also an important
factor in carcinogenesis. Thus, quenching of these reactive
intermediates or radicals by chemopreventive agents like
plant derived anti-oxidants is another important strategy
for attenuation of carcinogenesis. In addition to directly
quenching reactive intermediates, chemopreventive agents
also quench reactive intermediates by activating certain
cellular anti-oxidant enzymes like catalase or ameliorating
their chemical transformation to carcinogenic products.
Furthermore, initiation event can be blocked by enhancing
cellular DNA repair [8].
Cellular Proliferation and Apoptosis
During carcinogenesis, initiated cells, after accumulating
environmental insults and mutations, transform and clonally
expand to give rise to tumor and this process is called
Fig. 2.  Schematic presentations of steps where chemopreven-
tive agents can inhibit phase I enzyme induction.
Chemopreventive agents can block the process of initia-
tion by inhibiting xenobiotic induced transcriptional up-
regulation of phase I enzymes either by competing for
receptor, inhibiting nuclear translocation of ligand and
receptor complex or by inhibiting the binding of receptor
ligand complex to specific promoter element.
X = XAP2; 90 = heat shock protein 90; L = ligand (ex-
ogenous/endogenous); XRE = xenobiotic response ele-
ment; C = chemopreventive agent.
Fig. 3.  Model representing putative signaling cascade modulat-
ed by chemopreventive agents for induction of phase II
enzymes. ROS modulation brought about by chemopre-
ventive agents activate signaling kinases which modify
NRF2. Modified NRF2 dissociates from its inhibitor
keap1 and translocates to nucleus where it heterodimer-
izes with other transcription factors and binds to ARE,
transactivating down stream genes.Cancer Chemoprevention & Herbal Antioxidants
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promotion. This process is generally characterized by two
important cellular events viz., cellular proliferation and
apoptosis. Cellular proliferation, under normal conditions is a
well regulated process where proliferation signals interplay
with cell cycle checkpoint proteins. However, in transformed
cells these regulatory processes are over-ridden to cause hyper
proliferation under the influence of certain promotion signals
like stress etc. Proliferation can be initiated by different
endogenous and exogenous signals like mitogenic stimuli like
growth factors, oxidative stress and hormones. Irrespective
of the stimuli certain cellular pathways and down stream
events remain similar in number of tissues and cell types.
Few of such bio-molecules or effectors are protein kinase C
(PKC family of proteins), PI3Kinase, MAP kinases like erk,
jnk, p38 etc. These kinases upon activation upregulate a
number of transcription factors like jun, fos, Nuclear factor
kappa B (NF-kB), c-myc etc. that in turn regulate cell pro-
liferation [9]. Thus, agents which can decrease activation
of these signaling molecules can suppress the proliferation
and hence promotion. Such agents are generally termed as
suppressors.
Another important cellular event exploited in chemo-
prevention is apoptosis, which is characterized by cell
shrinkage, membrane blebbing, chromatin condensation and
DNA fragmentation. Induction of apoptosis or cell cycle
arrest by elimination of cells under stress or genetically
damaged cells may represent a protective mechanism by
which chemopreventive agents can inhibit promotion/pro-
gression stages of carcinogenesis. General mechanisms for
induction of apoptosis are hypothesized to be via stress
signals elicited by chemopreventive agents that lead to the
loss of mitochondrial membrane potential followed by release
of cytochrome c. Consequently, an apoptosome is formed by
the cytochrome c, apoptotic protease activating factor-1
(APAF-1) and caspase 9, which later results into activation
of downstream effector caspases [10]. Loss of mitochondrial
membrane potential is also inhibited by Bcl2 (anti-apoptotic
protein) or induced by Bax (proapoptotic protein). Further-
more, dietary agent induced activation of p53 (activator
of bax) can also mediate apoptosis in response to DNA
damage [11]. Hence, chemopreventive agents can alter the
trigger for apoptosis by altering the expression of anti/pro-
apoptotic proteins, which in turn regulate mitochondrial
membrane potential and caspase activation. Chemopreventive
antioxidants can also induce apoptosis by modulating acti-
vation of certain transcription factors such as NF-kB and
AP1 family members which are involved in induction of cell
survival genes (Fig. 4).
Herbal Compounds as Chemopreventive Agents
Among various chemopreventive compounds, dietary
agents, due to their high tolerability and low toxicity are
fast becoming lucrative targets. Based on experimental
and epidemiological evidences, chemoprevention or dietary
intervention especially employing herbal anti-oxidants is
receiving increasing attention as they have shown anti-
initiating and/or anti-promoting activities in experimental
systems [4]. Tabulated below is a partial list of plants
reported to possess chemopreventive potential along with
probable active component(s) and their mode(s) of action
(Table 1).
Few of the compounds like epigallocatechin gallate
(green tea catechin), curcumin, indole-3-carbinol, resvera-
trol, etc. mentioned in Table 1 are currently undergoing clin-
ical trials [12]. Of the many chemopreventive agents listed
in the Table 1, we have focused our studies on turmeric and
black tea.
Studies on Chemopreventive Efficacies of Turmeric
The powdered rhizome of the plant Curcuma longa
known as turmeric has number of medicinal properties.
Studies in our lab have shown turmeric and its active
Fig. 4.  Schematic presentations of signaling cascade where
chemopreventive agents act as a suppressor. Chemopre-
ventive agent can act as a suppressor either by inhibiting
signaling kinases that activate transcription factor like
AP-1 and NF-kB which in turn activate cell proliferation
genes or by inducing apoptosis via activation of proapo-
ptotic proteins like bax. C = chemopreventive agent;
wt = wild type.R. Patel, et al.
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Table 1. List of plants possessing chemopreventive activities
No Plant name [Reference] Active Compound(s) Mode of Action
1 Aegle marmelos [36] Marmelosin Anti-initiating
Luvangetin Anti-proliferative
2 Allium sativum (Garlic) [37] Diallyl sulphide Anti-initiating
S-methyl cysteine Anti-promoting
3 Allium cepa (Onion) [38] Diallyl sulphide Anti-initiating
S-methyl cysteine Anti-promoting
Selenium
4 Aloe vera (Ghritakumari) [39] Emodin Anti-mutagenic
Salicylates Anti-initiating
5 Alpinia officinarum (Galanga) [40] Galangin Anti-initiating
Anti-promoting
6 Andrographis paniculata Andrographolide Anti-initiating
(Kalmegh, Bhunimba) [41] Anti-promoting
7 Azadirachta indica (Neem) [42] Anti-initiating
Nimbolide Anti-promoting
8 Boswellia serrata [43] Boswellic acids Anti-proliferative
9 Brassica juncea (Mustard and Sulforaphane Anti-initiating
cruciferous vegetables) [44] Indole 3-carbinol
10 Camellia sinensis (Green and Flavonoids Anti-initiating
Black tea) [45] Catechins Anti-promoting
11 Capsicum annum (Red chilli) [46] Capsaicin Anti-promoting
12 Coriandrum sativum Linalool Anti mutagenic
(Coriander) [47] Monoterpenes
13 Curcuma longa (Turmeric) [48] Curcumin Anti-initiating
(Curcuminoids) Anti-promoting
14 Emblica officinalis (Amla) [49] Tannins Anti-promoting
Flavonoids
Pyrogallol
15 Eugenia caryophyllus (Clove) [50] Eugenol Anti-promoting
Isoeugenol
16 Foeniculum vulgare (Sweet fennel) [51] Anethole Anti-promoting
17 Garcinia indica (kokum) [52] Garcinol Anti-promoting
Anti-oxidant
18 Glycyrrhiza glabra (Licorice, Glycyrrhizin Anti-promoting
Yastimadhu) [53] Glycyrrhizic acid
19 Commiphora mukul (Guggulu) [54] Guggulsterone Anti-promoting
20 Glycine max (Soyabean) [55] Genistein Anti-promoting
21 Nerium oleander (Oleander) [56] Oleandrin Anti-promoting
22 Ocimum sanctum (Tulsi) [57] Ursolic acid Anti-promoting
Eugenol
23 Picrorhiza kurroa (Kutki) [58] Picroliv Anti initiating
24 Pinecone ginger (Zingiber Zerumbone Anti-initiating
zerumbet) [59] Anti-promoting
25 Punica granatum (Pomegranate) [60] Elagic acid Anti-promoting
26 Silybum marianum (Silymarin) [61] Silibinin Anti-initiating
Anti-promoting
27 Vitis vinifera (Grapes) [62] Resveratrol Anti-initiating
Anti-promoting
28 Withania somnifera (Ashwagandha) [63] Withonalides Anti-initiating
Anti-promoting
29 Zingiber officinale (Ginger) [64] Gingerol Anti-promoting
ParadolCancer Chemoprevention & Herbal Antioxidants
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compound curcumin, to inhibit carcinogen induced mutation
in the Ames assay and tumorigenesis in several experimental
systems suggesting anti-initiating and/or anti-promoting
activity against several chemical carcinogens [13–15]. Both in
vitro and in vivo studies have shown the efficacy of turmeric/
curcumin in inhibiting the carcinogen induced activity of
various CYP450s isozymes [16, 17] and enhancement of
phase II enzymes [18] resulting in decreased levels of
carcinogen derived DNA adducts [17,  19]. However, the
molecular basis of observed antiinitiation mechanism needs
to be evaluated further.
Chemoprevention and Black Tea
Tea is fast emerging as a potential chemopreventive
beverage and green tea is now a well established chemo-
preventive beverage and its biological activities are attributed
to certain active flavanols like epigallocatechin gallate
(EGCG) etc. Similar chemopreventive efficacy needs to be
investigated for black tea (and its polyphenols), which is a
widely consumed beverage. Since polymeric black tea
polyphenols (PBPs) or thearubigins (TRs) comprise almost
54% of the total polyphenols in black tea, studies on chemo-
prevention in our lab are focused on these fractions. PBPs
were isolated from black tea brew as five different fractions
(PBP1 to PBP5) by liquid-liquid and solid-liquid extraction
by exploiting their property of selective solubility in different
solvents and were partially characterized by NMR and FTIR
analysis [20].  In vivo studies indicated that, like green
tea polyphenols, PBPs can inhibit carcinogen-induced up
regulation of phase I enzymes like CYP450s and induce
phase II detoxifying enzymes thus decreasing the load of
DNA adduct formation [21–24]. Furthermore, PBPs have
also shown anti-promoting properties in experimental skin
carcinogenesis [unpublished observations].
Screening for Chemopreventive Efficacy
Putative chemopreventive agents are subjected to rigorous
in vitro and  in vivo screening assays to determine their
efficacies against different stages of carcinogenesis, in
defined model systems and investigate the mechanism(s) of
chemomodulation [25].  In vitro assays are employed as
rapid screens for determining the chemopreventive efficacy
based on modulation of different events presumed to be
mechanistically linked to carcinogenesis. In these evaluations,
biochemical assays, bacterial or mammalian cell systems,
cell lines, cell free extracts etc. are employed. Chemo-
preventive agents are screened for their abilities to inhibit
carcinogen/mutagen-induced effects (mutagenic/clastogenic
effects, adduct and free radical formation, effect on metabolic
and repair enzymes etc.) or to inhibit cell proliferation or to
enhance cell differentiation and apoptosis [26, 27].
These tests have generated voluminous and useful infor-
mation about the chemopreventive properties and mechanism
of action of large number of environmental agents (under
defined conditions). However, these properties are not
always reproducible in in vivo systems. Probable reasons for
these differences are: (a) doses of chemopreventive agent(s)
employed in in vitro studies are not achievable in vivo, (b)
metabolic incompetance and lower inducibility of metabolic
enzymes in cell lines as compared to tissues, (c) pharma-
cokinetics in the two system(s) and (d) lack of proper
controls (e.g. normal cell counterpart for studies on cancer
cell lines). Therefore, in vivo assay systems are essential for
evaluation of chemopreventive potential.
Animal models are central to the theme of disease prevention
as the data of short-term or long-term exposure of chemo-
preventive agents can be accrued by exploiting the short
lifespan of animal models. In vivo studies allow us to take a
closer look at signaling mechanisms and drug metabolism,
forming an integral part of preclinical studies. Many animal
models are available for testing the efficacy of chemo-
preventive agents.
Selection of model system is generally governed by their
rapidity, expression of multi stage carcinogenesis, organ/
tissue specificity, hormone responsiveness, invasiveness,
slow/fast growth of tumor, histological types and particular
relevance to most common human cancers.
In these assays, chemopreventive activity of an agent
is generally investigated against carcinogen(s)-induced
tumors or appropriate biomarkers in experimental animals.
In experimental animals chemopreventive activity is judged
either by increase in latency period or decrease in incidence
and multiplicity of carcinogen or spontaneously induced
tumors or by inhibition of carcinogen-induced alterations
or development of pre-malignant lesions [25]. In some
instances regression of tumor or attenuation of xenograft
growth and metastasis is also investigated [28, 29].
Genetically engineered mouse models have also been
employed to develop specific types of cancer or to sub-
stantially mimic human cancers e.g. APCmin,  carries a
germline truncation of one APC allele and develop multiple
intestinal adenomas [30]. This approach is very helpful in
demonstrating the role of defined molecular target or
pathway in carcinogenesis and chemoprevention.
Studies employing animal models have contributed signif-
icantly in identification of number of chemopreventive agents
and also helped in understanding the complexity of gene-
environment interactions. However, a major drawback of
assays employing animal models to study chemopreventive
efficacies is shorter experimental duration than the inherent
lifespan of animals. Due to this, adverse effects (if any) of
chemopreventive agents exhibited at later time point may be
missed. Several experimental studies have shown that some
of the chemopreventive agent(s) have been observed to beR. Patel, et al.
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carcinogenic under certain experimental conditions while
some other agent(s) have been observed to be protective
in one organ and enhance the risk in another organ [31].
Based on several of these observations, multi-organ
model(s) for evaluation of chemopreventive activity of
environmental agent(s) have been proposed where multi-
organ carcinogenesis is initiated using multiple organ-
specific carcinogens along with exposure to chemopreventive
test compound prior, during and after carcinogen exposure
to evaluate its chemopreventive effects against different
carcinogens in different organs. In few, such studies it
was observed that certain chemopreventive agents might
promote carcinogenesis in animals challenged with more
than one carcinogen as compared to animals challenged with
only one specific carcinogen. Caution needs to be exercised
while executing and analyzing such experimental data since
over burdening animals with number of carcinogens at
optimum carcinogenic doses might render certain organs
like liver under excess stress which might be one of the
reasons of promoting carcinogenesis [31]. Such drawbacks can
be dealt with by subjecting the animals to sub-carcinogenic
doses of different carcinogens and analyzing molecular
markers instead of frank tumors as the end point. However,
rodents differ from humans in many ways that are relevant to
cancer such as oncogenic signaling, length of telomeres,
extent of karyotypic abnormalities, basal metabolic rate and
non-epithelial origin of murine malignancies as compared
to epithelial origin of human malignancies. These suggest
rodent models may not accurately reflect the cellular
carcinogenesis and may require caution in extrapolating
data from murine neoplasia studies directly to humans.
Nonetheless, animal studies are of prime importance not
only as confirmatory studies employing various models with
different dose regimes but also for better understanding of
molecular pathways.
Chemoprevention: Current Status and Future Per-
spectives
After establishment of pre-clinical efficacy of an agent, it
further undergoes phase I, II and III clinical trials to test their
safety, and efficacy in human situation [25]. Being relatively
less toxic, dietary agents have advantage over other
synthetic agents. But inspite of this most of the agents, that
have emerged highly promising after pre-clinical safety and
efficacy studies, have failed in human trials [32].
These failures broadly can be grouped into two distinct
outcomes viz., adverse effects or null effect. The failure of
the beta carotene trial for prevention of lung cancer in high
risk population has chanalized rest of the preclinical studies
on putative chemopreventive agents towards mechanistic
aspects of the observed anticarcinogenic effects rather than
focusing only on end points. The advent of more sensitive
assays like expressional arrays enables a bird’s eye view
of effect of particular chemopreventive agent at cellular,
organ and entire organism level which will not only impart
better understanding of the safety but also aid in identifying
appropriate biomarker. The null effects of potential chemo-
preventive agents in clinical trials can be attributed to
number of issues, which need increased attention. One such
issue is individual differences in host susceptibility which in
turn are governed by genetic constitution. Certain families of
genes associated with xenobiotic metabolism, DNA repair
etc. have functional single nucleotide polymorphisms,
which may influence carcinogenesis and hence even chemo-
prevention [32]. The choice of target population for chemo-
prevention is another such issue as considering risk to benefit
ratio, most logical population as target for chemoprevention
would be high risk individuals. However, identification of
such individuals for most cancers, such as oral cancer, is
highly challenging due to diverse complexities of individual
variations and gene-environment interactions. Moreover,
anti-oxidants used as chemopreventive agents depending on
the cellular milieu, can also act as pro-oxidants [32]. Choice
of dietary chemopreventive agents as active compounds or
whole plant extracts, dose, duration and mode of application
for particular target population against specific cancers is
also very critical. Use of dietary agents for chemoprevention
also emphasizes nutritional studies, which encompass certain
aspects like interactions of chemopreventive supplements
with normal diet and host factors. Thus, clinical evaluation
based on mechanistic studies, gene-environment interactions
and complementing nutritional studies constitute the major
thrust areas in chemoprevention research [33–35].
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